Design, development and evaluation of Resveratrol transdermal patches for breast cancer therapy.
Int J Pharm
; 632: 122558, 2023 Feb 05.
Article
em En
| MEDLINE
| ID: mdl-36592891
ABSTRACT
Resveratrol (RVT) is a polyphenolic phytoestrogen which has shown antiproliferative activity in breast cancer. However, its low bioavailability and short half-life have restricted its use. The current study aimed to develop transdermal patches of RVT and evaluate its site-specific delivery for breast cancer therapy. Different penetration enhancers were screened using a computational tool, quantitative structure propery relationship (QSPR). The best permeation of RVT was observed in a patch comprising hydroxypropyl methylcellulose (HPMC) E15LV HPMC-K4M polyvinyl pyrrolidone (PVP) K30 in the ratio of 312 as release controlling polymers with GlycerolCapryol 90 (41) as penetration enhancer and plasticizer. To assess the localized delivery of RVT, the patch was applied to the breast of female rats. Higher breast tissue disposition with lower systemic concentration was observed compared to oral administration, demonstrated by increased AUC and MRT. Further, the optimized RVT patches were tested in 7,12-Dimethylbenz[a]anthracene (DMBA) induced rat mammary cancer. Compared to oral RVT, the application of RVT tansdermal patches significantly reduced the tumor volume and serum CA 15-3, a cancer biomarker. Thus, the RVT transdermal patch may be a viable approach for ensuring high local concentration of drug for site-specific delivery in breast cancer therapy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Absorção Cutânea
/
Neoplasias
Limite:
Animals
Idioma:
En
Revista:
Int J Pharm
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Índia